Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
5.13
+0.32 (6.65%)
At close: May 12, 2025, 4:00 PM
4.880
-0.250 (-4.87%)
After-hours: May 12, 2025, 6:40 PM EDT
Cogent Biosciences Employees
Cogent Biosciences had 205 employees as of December 31, 2024. The number of employees increased by 41 or 25.00% compared to the previous year.
Employees
205
Change (1Y)
41
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,314,620
Market Cap
584.48M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 205 | 41 | 25.00% |
Dec 31, 2023 | 164 | 26 | 18.84% |
Dec 31, 2022 | 138 | 61 | 79.22% |
Dec 31, 2021 | 77 | 62 | 413.33% |
Dec 31, 2020 | 15 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
COGT News
- 6 days ago - Cogent Biosciences Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 17 days ago - Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 2 months ago - Cogent Biosciences Announces Participation in the Leerink Healthcare Conference - GlobeNewsWire
- 2 months ago - Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - GlobeNewsWire
- 2 months ago - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting - GlobeNewsWire
- 3 months ago - 3 Biotech Stocks With Notable Insider Buying - Seeking Alpha